Biggest News Aggregation in the World
📰 Ruby Trial News

Page 2 - Ruby Trial News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Ruby Trial. Real-time updates on events, politics, business and more.

EMA Validates Type II Variation Application for Dostarlimab/Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

The European Medicines Agency has validated a type II variation for potential approval of dostarlimab in combination with carboplatin and paclitaxel for the treatment of patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.
Hesham Abdullah European Medicines Agency Committee For Medicinal Products Human Medicinal Products Human Use New England Journal

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Mansoor R. Mirza, MD, reviews data from the phase 3 RUBY trial investigating dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer.
Mansoorr Mirza Primary Advanced Recurrent Endometrial Cancer Placebo Controlled Randomized Phase Endometrial Cancer Advanced Endometrial Cancer

Dostarlimab Plus Chemotherapy Shows Survival Benefit, Fills Unmet Need for Patients With Recurrent Endometrial Cancer

Combining the immune checkpoint inhibitor dostarlimab-gxly with standard-of-care chemotherapy elicited an increase in progression-free survival rates compared with chemotherapy alone for patients with primary advanced or recurrent endometrial cancer.
Mansoor Raza Mirza Copenhagen University Hospital Nordic Society Of Gynecologic Oncology European Network For Gynecological Oncological Trial Department Of Oncology Society Of Gynecological Oncology

Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer

Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.
Copenhagen University Hospital Department Of Oncology Society Of Gynecological Oncology Gynecological Oncology Annual Meeting Chief Oncologist

CNN Reliable Sources with Brian Stelter June 6, 2021 15:22:00

Donald trump in the news cycle every day, youre seeing a decrease in the amount of people clicking on stories, watching cable news, et cetera. >> originally i booked you here dan to talk about the new book "kennedy avenge". >> frankly there was a lot i didnt know until i opened this up. so i wonder, since your book shows that a lot of jfk conspiracies stemmed from the ruby trial, are there lessons from those conspiracy theories in the 60s to today. >> i think it is a lot about what were talking ...
Et Cetera Donald Trump News Cycle Watching Cable News Ruby Trial Jfk Conspiracies

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science